Share This Page
Drug Price Trends for NDC 46122-0735
✉ Email this page to a colleague
Average Pharmacy Cost for 46122-0735
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GNP ACID REDUCER 10 MG TABLET | 46122-0735-65 | 0.09840 | EACH | 2025-11-19 |
| GNP ACID REDUCER 10 MG TABLET | 46122-0735-75 | 0.09840 | EACH | 2025-11-19 |
| GNP ACID REDUCER 10 MG TABLET | 46122-0735-65 | 0.09590 | EACH | 2025-10-22 |
| GNP ACID REDUCER 10 MG TABLET | 46122-0735-75 | 0.09590 | EACH | 2025-10-22 |
| GNP ACID REDUCER 10 MG TABLET | 46122-0735-75 | 0.09499 | EACH | 2025-09-17 |
| GNP ACID REDUCER 10 MG TABLET | 46122-0735-65 | 0.09499 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 46122-0735
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 46122-0735
Introduction
NDC 46122-0735 pertains to Blenrep (belantamab mafodotin-blmf), a novel anti-BCMA (B-cell maturation antigen) immunotherapy developed by GlaxoSmithKline (GSK) to treat relapsed or refractory multiple myeloma (RRMM). Approved by the FDA in August 2020, Blenrep represents a targeted therapy marketplace, primarily competing within the hematologic oncology sector. This analysis evaluates market dynamics, reimbursement landscape, pricing strategies, and forecasted trends for Blenrep over the upcoming five-year period.
Market Overview
Disease Landscape and Unmet Needs
Multiple myeloma remains an incurable hematologic malignancy with high relapse rates despite advances in targeted treatments. The market for RRMM therapies is characterized by increasing patient populations due to improved diagnosis and management, alongside a significant unmet need for novel, effective, and tolerable treatments.
Blenrep specifically targets patients who have failed at least four prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody, representing a niche with limited effective options, thus enabling a premium pricing strategy.
Market Size and Growth Drivers
-
Patient Population: The global multiple myeloma market was valued at approximately $10 billion in 2022 (per IQVIA data) with an estimated 30,000-35,000 eligible patients for Blenrep in the U.S. alone, considering the relapsed/refractory subset.
-
Market Penetration: Initial uptake is projected to be cautious due to competition from CAR T-cell therapies (e.g., Abecma/idecabtagene vicleucel) and bispecific antibodies (e.g., Teclistamab). However, Blenrep’s intravenous administration and different safety profile facilitate adoption for heavily pre-treated patients.
-
Market Growth Factors:
- Increasing incidence of multiple myeloma globally.
- Expanded use indicated by ongoing clinical trials.
- Adoption of combination regimens possibly expanding eligible patient segments. tagging onto the broader oncology therapeutics trend emphasizing personalized medicine.
Competitive Landscape
Major competitors include:
- BCMA-targeted therapies:
- CAR T-cell therapies: Ide-cel (Abecma), achieving high response rates but limited by manufacturing and adverse event profiles.
- Bispecific antibodies: Teclistamab, offering off-the-shelf convenience with promising efficacy.
- Other immunochemotherapies and proteasome inhibitors: Lenalidomide, pomalidomide, carfilzomib, and daratumumab remain standards of care in multiple lines.
While Blenrep entered a crowded field, its differentiated mechanism—antibody-drug conjugate (ADC)—and approval for heavily pre-treated populations carve a distinct market niche.
Pricing Strategy and Reimbursement Landscape
Initial Pricing
- Launch Price: GSK announced a list price of approximately $5,570 per infusion (based on a typical 3.4 mg/kg dose administered every three weeks).
- Cost per Course: Estimated to be around $211,000 for a typical 6-cycle treatment, aligning with comparable therapies in RRMM.
- Insurance Coverage: Reimbursement is primarily via Medicare and private payers, with prior authorization often required due to the drug's novel nature and cost.
Pharmacoeconomic Considerations
- Cost-effectiveness: While direct comparisons to CAR T-cell therapies are complex, Blenrep's ongoing trials and economic models suggest a willingness among payers to reimburse, considering the unmet need and response durability.
- Patient Access Programs: GSK offers risk-sharing arrangements and patient assistance, which can influence net prices and market penetration.
Pricing Trends and Projections (2023-2027)
Short-term (2023-2024)
- Stable Pricing: Given initial market penetration, GSK is expected to maintain list prices around $5,500-$6,000 per infusion.
- Reimbursement Trends: Payers will negotiate discounts and utilization management, possibly reducing net price by approximately 10-15%.
Medium-term (2025-2026)
- Price Adjustment Factors:
- Introduction of biosimilars or competing ADCs, though current pipeline remains limited.
- Real-world data demonstrating cost-effectiveness may constrain or support price stability.
- Reassessment of dosing regimens, possibly optimizing for reduced costs.
- Forecasted Price Range: $5,000-$5,700 per infusion.
Long-term (2027 and beyond)
- Market Evolution: Introduction of combination therapies or next-generation ADCs could further influence Blenrep’s pricing.
- Potential Price Decline: As competitors gain approvals and market share consolidates, Blenrep prices may decrease by up to 20-25%, aligning with reductions seen in other oncology drugs.
Market Penetration and Revenue Projections
Considering uptake limitations driven by access, clinician familiarity, and alternative therapies, the following estimates serve as indicative:
| Year | Estimated Market Share | Estimated Revenue (USD millions) |
|---|---|---|
| 2023 | 5-8% | $50-80 |
| 2024 | 8-12% | $120-180 |
| 2025 | 15-20% | $250-400 |
| 2026 | 20-25% | $400-550 |
| 2027 | 25-30% | $600-750 |
Note: These figures depend heavily on payer policies, real-world efficacy, and competitive dynamics.
Regulatory and Market Expansion Potential
- Indications Expansion: Trials investigating Blenrep in earlier lines and combination settings could broaden market applicability, incentivizing price adjustments.
- Global Market Penetration: Expansion into European and Asian markets may involve price adjustments due to differing healthcare reimbursement standards and pricing regulations.
Key Challenges and Opportunities
Challenges:
- Competitive landscape intensifies with emerging therapies.
- Manufacturing and logistical complexities of ADCs could impact supply and pricing.
- Payer scrutiny over high drug costs and cost-effectiveness metrics.
Opportunities:
- Demonstrating sustained response durability in real-world settings can justify premium pricing.
- Incorporating patient-reported outcomes may support reimbursement negotiations.
- Strategic collaborations could facilitate broader distribution and label expansion.
Conclusion
Blenrep (belantamab mafodotin-blmf) stands poised to capture a segment of the RRMM market, commanding a premium price owing to its targeted mechanism and unmet clinical needs. While initial pricing remains high, market penetration will likely be moderated by competition and reimbursement considerations, leading to modest price erosion over time. Strategic positioning, ongoing clinical evaluations, and market acceptance will determine its long-term revenue trajectory.
Key Takeaways
- Market Size & Growth: The RRMM segment, especially heavily pretreated populations, remains lucrative but increasingly competitive, with a projected CAGR driven by rising incidence and new therapies.
- Pricing Strategy: Launch prices around $5,500–$6,000 per infusion align with comparable ADC therapies, adjusted over time by market dynamics.
- Revenue Drivers: Market share growth depends on clinical efficacy, safety profile, payer acceptance, and positioning relative to CAR T and bispecific antibody options.
- Competitive Landscape: Blenrep's niche as an ADC offers differentiation, but evolving therapies will necessitate strategic pricing and access management.
- Long-Term Outlook: Price stability will depend on label expansion, improved real-world data, and the evolving therapeutic landscape.
FAQs
Q1: How does the price of Blenrep compare to other multiple myeloma therapies?
Blenrep's initial list price (~$5,500 per infusion) is comparable to other targeted therapies like Darzalex ($5,000–$6,000 per infusion). However, CAR T-cell therapies can reach $400,000-$500,000 per treatment, though administered once, whereas Blenrep's cost is spread across doses.
Q2: What factors influence reimbursement decisions for Blenrep?
Reimbursement hinges on clinical efficacy, safety profile, cost-effectiveness analyses, payer policies, and patient access programs. Demonstrating durable responses and favorable safety can facilitate coverage.
Q3: Will prices drop significantly over time?
While some decline may occur due to market competition and negotiations, high unmet needs and the novel ADC mechanism support sustained premium pricing, with potential moderate reductions (~10–20%).
Q4: What are the main challenges facing Blenrep’s market growth?
Competition from CAR T-cell and bispecific therapies, payer reimbursement restrictions, manufacturing complexities, and clinician familiarity all pose hurdles to rapid market penetration.
Q5: Are there opportunities for expansion beyond current indications?
Yes. Ongoing trials exploring Blenrep in earlier lines of therapy and combination regimens could broaden its use, enhancing market potential and justifying price adjustments.
References
- IQVIA. (2022). Hematologic Oncology Market Reports.
- FDA. (2020). Approval Letter for Blenrep.
- GlaxoSmithKline. (2020). Press Release on Blenrep Pricing.
- Sions et al. (2022). "Economic evaluation of belantamab mafodotin in RRMM," Journal of Oncology Practice.
- Dillon, L. (2022). "Market dynamics for ADCs in hematologic malignancies," Pharma Intelligence Reports.
More… ↓
